|
EP2124899A2
|
|
Stable pharmaceutical formulations of atorvastatin magnesium salt
|
|
US2007134329A1
|
|
Venlafaxine formulations and methods of preparing the same
|
|
WO2007091279A1
|
|
Formulations of clopidogrel bisulphate
|
|
EP1904038A2
|
|
Compressed pharmaceutical composition comprising coated pellets and a direct compression mixture, and method of preparation thereof
|
|
EP1865927A1
|
|
Topiramate tablet formulation
|
|
CN101132764A
|
|
Rapidly disintegrating dosage form comprising magnesium carbonate heavy
|
|
WO2005115346A2
|
|
Pharmaceutical composition containing risperidone
|
|
EA011862B1
|
|
Formulations of ramipril
|
|
EP1776089A2
|
|
Donepezil formulations
|
|
AU2004312059A1
|
|
Atomoxetine formulations
|
|
EP1763337A2
|
|
Immediate, controlled and sustained release formulations of galanthamine
|
|
EP1713451A1
|
|
Solid dosage formulations of galanthamine
|
|
EA011579B1
|
|
Sustained release formulations of venlafaxine
|
|
EP1575555A2
|
|
Formulations of finasteride
|
|
NZ538615A
|
|
Use of CGRP antagonist compounds for treatment of psoriasis
|
|
UA78988C2
|
|
Pharmaceutical formulation comprising fosinopril
|
|
UA78542C2
|
|
Formulations of quinapril and other ace inhibitors
|
